(1 g/day, orally) for a median duration of 7 months (range, 6-11 months) initially, whereas the remaining patients (9 Stage B patients and 7 Stage C patients) received 1 Department of Medical Oncology, Ibn-i Sina combination chemotherapy (cyclophosphamide, vincristine, procarbazine, and Hospital, Ankara University School of Medicine, prednisolone [COPP regimen]) followed by tetracycline at a dose of 1 g/day for 6 Sihhiye-Ankara, Turkey.more months in patients with complete response (CR) after the COPP regimen. 2 Department of Gastroenterology, Ibn-i Sina
RESULTS. The median follow-up was 68 months (range, 38-89 months). As first-Hospital, Ankara University School of Medicine, line therapy in Stage A patients, tetracycline yielded a 71% CR and 43% disease Sihhiye-Ankara, Turkey.free survival (DFS) rate. Eleven of 16 patients (69%) with Stage B or C disease who 3 Department of Third Internal Medicine, SSK received the COPP regimen achieved CR and only 2 patients had a recurrence Hospital, Diskapi-Ankara, Turkey.(DFS rate of 56%). The 5-year overall survival (OAS) rate for the entire group was 70%, and the 5-year DFS rate for patients with CR was 75%. However, the median